Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prophylactic vs On-demand Tocilizumab in CAR-T Recipients
NCT06430736Phase 2Recruiting
- Sponsor
- Insel Gruppe
- Start
- Jul 2024
- Primary completion
- Dec 2026
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of tocilizumab in cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), sponsored by Insel Gruppe. Started Jul 2024; status: recruiting.
02
Drugs
tocilizumab
03
Conditions
cytokine release syndrome (CRS)immune effector cell-associated neurotoxicity syndrome (ICANS)
Beyond the preview
Go deeper on NCT06430736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06430736.